Findings

What do systematic reviews say?

25 questions · 25 findings · 6 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 18 · 72%GRADE not reported 0 · 0%Very low 6 · 24%Low 1 · 4%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Serious adverse events (number) · people with acute pancreatitis

1 finding from 1 review

Pharmacological interventions for acute pancreatitis 2017 · Cochrane Headline outcomes only
0.86 [0.68, 1.07]
12 studies · 716 participants
Very low

Colchicine vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Insulin plus glucagon vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propylthiouracil vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glucocorticosteroids vs no intervention

Serious adverse events (number) · participants with severe alcoholic hepatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pentoxifylline vs no intervention

Serious adverse events (number) · participants with severe alcoholic hepatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anabolic steroids vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glucocorticosteroids vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antioxidants vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propylthiouracil vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pentoxifylline vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thiazolidinediones vs no intervention

Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)

It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).

1 finding from 1 review

Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) 2017 · Cochrane Headline outcomes only
rate ratio 0.25 [0.06, 1.05]
3 studies · 357 participants
Very low

Antioxidants vs no intervention

Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)

It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).

1 finding from 1 review

Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) 2017 · Cochrane Headline outcomes only
rate ratio 0.89 [0.36, 2.19]
2 studies · 254 participants
Very low

Bile acids vs no intervention

Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)

It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).

1 finding from 1 review

Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) 2017 · Cochrane Headline outcomes only
Rate ratio 1.01 [0.66, 1.54]
3 studies · 404 participants
Very low

Colchicine vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ciclosporin vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

D‐Penicillamine vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found